The Worry About Clopidogrel “Nonresponsiveness” Identification and Treatment in the Post-Percutaneous Coronary Intervention Patient⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology. by Gurbel, Paul A. et al.
ET
C
I
P
P
A
B
A
t
a
o
s
a
r
p
e
o
r
d
c
p
p
M
r
B
o
i
p
a
D
i
d
H
p
l
r
t
p
c
C
M
a
p
a
t
P
r
f
i
C
a
a
a
l
m
(
t
d
s
t
r
c
m
c
d
T
s
n
w
u
i
l
a
T
1
r
p
l
e
i
p
f
a
*
a
t
‡
U
r
S
h
S
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 2 , N O . 1 1 , 2 0 0 9
© 2 0 0 9 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 0 9 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 0 9 . 0 9 . 0 0 5DITORIAL COMMENT
he Worry About
lopidogrel “Nonresponsiveness”
dentification and Treatment in the
ost-Percutaneous Coronary Intervention Patient*
aul A. Gurbel, MD,† Udaya S. Tantry, PHD,†
lan R. Shuldiner, MD‡
altimore, Maryland
rguably, antiplatelet agents are the most important
herapy we administer to stented patients. Antiplatelet
gents are given to prevent the most dreaded event that
ften has catastrophic consequences, coronary thrombo-
is. It is well established that platelet reactivity to
denosine diphosphate (ADP) mediated by the P2Y12
eceptor plays a central role in the development of
ost-percutaneous coronary intervention (PCI) ischemic
vents, including stent thrombosis. The active metabolite
f clopidogrel blocks this pivotal receptor (1,2). Platelet
See page 1095
eactivity to ADP during clopidogrel therapy has been
etermined by turbidimetric aggregometry, VerifyNow (Ac-
umetrics, San Diego, California) assay, Thrombelastogra-
hy (TEG, Hemonetics, Braintree, Massachusetts), Multi-
late Analyzer (Dynabyte Informationssysteme GmbH,
unich, Germany), and flow cytometry to measure phospho-
ylated vasodilator stimulated phosphoprotein (VASP Assay,
iocytex, Marseille, France). All of these methods have dem-
nstrated clopidogrel response variability, and have been used
n translational research studies to demonstrate that selected
atients with high on-treatment platelet reactivity to ADP are
t increased risk for post-PCI ischemic event occurrence (3).
espite the compelling evidence that the effect of clopidogrel
s variable and high platelet reactivity during therapy is a
efinite risk factor for recurrent ischemic events, the American
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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niversity of Maryland School of Medicine, Baltimore, Maryland. Dr. Gurbel
eceives grant support from Schering-Plough, AstraZeneca, Bayer Healthcare,
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onoraria/consulting income from Schering-Plough, AstraZeneca, Bayer Healthcare,
anofi-Aventis, Portola Pharmaceuticals, Daiichi-Sankyo, Lilly, and Pozen.eart Association, American College Cardiology, and Euro-
ean Society of Cardiology guidelines and current practice
argely employ a uniform, “one-size-fits-all” clopidogrel dosing
egimen in the PCI patient. Therein lies the major paradox
hat Gladding et al. (4) attempt to address in their study of
harmacogenetic testing in the PCI patient.
Clopidogrel is a prodrug that is activated by hepatic cyto-
hrome (CYP) P450 isoenzymes including CYP2C19,
YP3A, CYP1A2, and CYP2B6 in a 2-step process.
ultiple lines of evidence strongly indicate that variable
nd suboptimal active metabolite generation are the
rimary explanation for clopidogrel response variability
nd nonresponsiveness (5). Recent studies have identified
he common loss-of-function cytochrome P450 (CYP
450) 2C19*2 allele as a major determinant of the
esponse to conventional dose clopidogrel and as a risk
actor for post-stenting ischemic events (5–7). This allele
s created by a guanine adenine mutation in exon 5 of
YP2C19 present in chromosome 10q24 that produces
n aberrant splice site leading to an altered reading frame
t amino acid 215 and a premature stop codon 20 amino
cids downstream. A nonfunctional protein and/or and
ack of translation results. This single nucleotide poly-
orphism (SNP) has a high prevalence in Caucasians
24%), African Americans (33%), and Asian popula-
ions (51%) (6). Nongenetic factors, including drug-
rug interactions at the CYP level involving lipophilic
tatins and calcium antagonists with CYP3A4, and pro-
on pump inhibitors (PPIs) with CYP2C19 have also been
eported to attenuate clopidogrel responsiveness. However, the
linical significance of these associations remains debated (5).
Gladding et al. (4) explore a critical question toward
ore individualized and effective dosing of clopidogrel:
an an increased dose of clopidogrel overcome genetically
etermined decreased-responsiveness to clopidogrel?
hey studied the antiplatelet effect of increasing the
tandard “one-size-fits-all” 75 mg/day clopidogrel mainte-
ance dose to 150 mg/day for 1 week in 39 patients, 88% of
hom had undergone PCI. The VerifyNow P2Y12 assay was
sed, and measurements were taken before and after the dose
ncrease. The investigators genotyped for the reduced/
oss-of-function SNPs, CYP2C19*2, *3, *4 and CYP2C9*2
nd *3, and the increased function, CYP2C19*17 SNP.
he primary hypothesis was that treatment with the
50-mg dose for 1 week would increase the antiplatelet
esponse in CYP2C19*2 carriers. On standard-dose clo-
idogrel therapy, carriers of the CYP2C19*2 allele had
ower platelet inhibition compared with noncarriers. The
ffect of the other CYP2C variants on clopidogrel-
nduced inhibition of platelet reactivity was less certain,
erhaps due to the limited sample size. Overall, they
ound a modest effect of the increased maintenance dose;
n 8.6  13.5% increase in platelet inhibition in
YP2C19*2 and *3 carriers suggesting that genotype-
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1103irected dosing of clopidogrel may play a role in deter-
ining who will respond to high-dose clopidogrel. How-
ver, the large standard deviation is strong evidence of
he variable response even to the 150-mg dose; indeed
ome carriers of the CYP2C19*2 variant had little or no
esponse to the higher dose. Furthermore, although it is
tated that those with the CYP2C19*2 allele had a greater
hange in platelet aggregation in response to the higher
ose of clopidogrel than noncarriers, it is unclear based
n an investigation of this size to determine the actual
requency of CYP2C19*2 carriers who will achieve the
ame level of platelet inhibition on higher-dose clopi-
ogrel as noncarriers on standard dose therapy. Similarly,
n a limited number of patients on PPIs (n  12), the
igher maintenance dose was associated with a 9  10%
ncrease in platelet inhibition. However, it is again
nclear from this study how effective the increased dose
n patients on PPIs will be in achieving the same level of
nhibition as those on standard-dose clopidogrel not on
PIs (4).
These data are concordant with prior studies (5–7). Al-
hough conclusive association between the CYP2C19*2 poly-
orphism (pharmacogenetic measurement), suboptimal active
etabolite generation (pharmacokinetic measurement), de-
reased clopidogrel responsiveness as measured by a platelet
unction assay (pharmacodynamic measurement), and poorer
linical outcomes have not yet been confirmed in a single study,
he effect of CYP2C19 genotype on clopidogrel response
ppears well established (6). A more thorough analysis of these
elationships will enhance our understanding of the mecha-
isms responsible for high post-PCI risk associated with
pecific SNPs that have been previously reported.
There are additional study design and methodological
aveats worthy of comment. First, there is no mention of
oncomitant aspirin therapy or dose, and aspirin has a
ose-dependent effect on platelet reactivity to ADP.
econd, the time of platelet function testing in relation to
he time of the last clopidogrel dose (both 75 mg and 150
g) is uncertain. Third, a true baseline platelet function
easurement in the absence of clopidogrel therapy was
ot made. Instead the authors refer to platelet “inhibi-
ion” based on platelet function stimulated by iso-
hrombin receptor activating peptide in the VerifyNow
ssay. Finally, as recognized by the investigators, there
as no determination of compliance. All of these limi-
ations may influence the results, particularly in light of
he relatively small sample size (4).
Despite these limitations, we agree with the primary
onclusion of the authors; higher clopidogrel dosing does
ower platelet reactivity in selected patients. The largest
linical study that addressed the clinical effect of 75 mg
ersus 150 mg clopidogrel maintenance therapy was the
URRENT–OASIS 7 (Clopidogrel optimal loading
ose Usage to Reduce Recurrent EveNTs–Organization Ao Assess Strategies in Ischemic Syndromes 7) acute
oronary syndrome trial recently reported at the Euro-
ean Society of Cardiology Congress (8). In this trial,
atients treated with the higher clopidogrel maintenance
ose also received a 600-mg load as compared with a
00-mg load administered to patients treated with the
onventional maintenance dose. In the PCI population,
he higher dose of clopidogrel was associated with a lower
ncidence of the 30-day primary ischemic end point but
n increased incidence of the CURRENT–OASIS 7
tudy defined major bleeding (8). It is uncertain from this
tudy whether high-dose clopidogrel has the same effects
n the nonacute coronary syndrome population or
hether the higher dose affects CYP2C19*2 carriers
ifferentially.
A major unresolved question is how to predict who will
chieve sufficient inhibition from the higher dose and/or
ho will need an alternative P2Y12 inhibitor. Are CYP2C
enotypes the predictive tool to address this question? Based
n the Gladding et al. (4) data, CYP2C genotyping alone
ould likely not provide the level of predictive value
equired for clinically effective decision making in this
atient population. As the investigators acknowledge, the
mall overall improvement observed may also not be clini-
ally relevant, and many CYP2C19*2 carriers had persistent
ow platelet inhibition. Since platelet function critically
nfluences the occurrence of thrombotic events in stented
atients, a diagnostic tool with higher sensitivity and spec-
ficity to predict whether a sufficient antiplatelet effect will
ccur is needed.
Based upon our current knowledge of clopidogrel
harmacogenetics and pharmacodynamics, we conclude
hat genotyping alone cannot be regarded as a surrogate
or platelet function testing in identifying clopidogrel
onresponders. Prospective large-scale studies are re-
uired to determine the clinical utility of CYP2C geno-
yping to guide personalized antiplatelet therapy. These
rials need to be adequately powered to assess clinical
fficacy as well as adverse bleeding events that may be
ssociated with increased clopidogrel dosing, especially in
ertain patient subgroups identified in the TRITON–
IMI 38 (TRial to assess Improvement in Therapeutic
utcomes by optimizing platelet InhibitioN with prasug-
el–Thrombolysis In Myocardial Infarction 38) trial who
ere at increased bleeding risk with the more potent
ntiplatelet agent prasugrel (i.e., age 75 years, weight
60 kg, and patients undergoing coronary artery bypass
raft) (9). The rapid genotyping methodology reported in
he current study will likely facilitate these investigations
nd potential future translation into clinical practice.
inally, multiple factors, both genetic and nongenetic,
etermine clopidogrel metabolism and its pharmacody-
amic response, and subsequent cardiovascular events.
lgorithms that incorporate CYP2C genotypes, point-
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1104f-care platelet aggregation testing, concurrent medica-
ion use, and other relevant factors may be more clinically
seful predictive tools to direct individualized dosing
nd/or choice of antiplatelet agent. Furthermore, variants
n other genes that influence clopidogrel response are
ikely to exist (6). Once discovered, genetic testing may
mprove predictive algorithms to guide more individual-
zed and effective antiplatelet regimens.
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